These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23028830)

  • 1. An accurate prostate cancer prognosticator using a seven-gene signature plus Gleason score and taking cell type heterogeneity into account.
    Chen X; Xu S; McClelland M; Rahmatpanah F; Sawyers A; Jia Z; Mercola D
    PLoS One; 2012; 7(9):e45178. PubMed ID: 23028830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
    Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
    Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
    Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
    Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Validation of an Individualized Immune Prognostic Signature for Recurrent Prostate Cancer.
    Jin Y; Wang L; Lou H; Song C; He X; Ding M
    Comb Chem High Throughput Screen; 2021; 24(1):98-108. PubMed ID: 32593277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases.
    Ong CW; Maxwell P; Alvi MA; McQuaid S; Waugh D; Mills I; Salto-Tellez M
    J Pathol Clin Res; 2018 Apr; 4(2):103-113. PubMed ID: 29665325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression.
    Agell L; Hernández S; Nonell L; Lorenzo M; Puigdecanet E; de Muga S; Juanpere N; Bermudo R; Fernández PL; Lorente JA; Serrano S; Lloreta J
    Am J Pathol; 2012 Nov; 181(5):1585-94. PubMed ID: 23083832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of the top-scoring pairs of genes for prediction of prostate cancer progression.
    Zhao H; Logothetis CJ; Gorlov IP
    Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):252-9. PubMed ID: 20386565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer.
    Ma C; Zhou Y; Fanelli GN; Stopsack KH; Fiorentino M; Zadra G; Mucci LA; Loda M; Tyekucheva S; Penney KL
    Mol Cancer Res; 2023 Mar; 21(3):253-260. PubMed ID: 36511902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect.
    Magi-Galluzzi C; Maddala T; Falzarano SM; Cherbavaz DB; Zhang N; Knezevic D; Febbo PG; Lee M; Lawrence HJ; Klein EA
    Oncotarget; 2016 Jun; 7(23):33855-65. PubMed ID: 27121323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort.
    Jhun MA; Geybels MS; Wright JL; Kolb S; April C; Bibikova M; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Oncotarget; 2017 Jun; 8(26):43035-43047. PubMed ID: 28496006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer.
    Abou-Ouf H; Alshalalfa M; Takhar M; Erho N; Donnelly B; Davicioni E; Karnes RJ; Bismar TA
    J Cancer Res Clin Oncol; 2018 May; 144(5):883-891. PubMed ID: 29511883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
    Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
    Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profiling of prostatic acinar morphogenesis identifies PDCD4 and KLF6 as tissue architecture-specific prognostic markers in prostate cancer.
    Li CR; Su JJ; Wang WY; Lee MT; Wang TY; Jiang KY; Li CF; Hsu JM; Chen CK; Chen M; Jiang SS; Weaver VM; Tsai KK
    Am J Pathol; 2013 Feb; 182(2):363-74. PubMed ID: 23219426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer.
    Goh LK; Liem N; Vijayaraghavan A; Chen G; Lim PL; Tay KJ; Chang M; Low JS; Joshi A; Huang HH; Kalaw E; Tan PH; Hsieh WS; Yong WP; Alumkal J; Sim HG
    PLoS One; 2014; 9(3):e91666. PubMed ID: 24626295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asporin is a stromally expressed marker associated with prostate cancer progression.
    Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
    Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Utility of a New mRNA Expression Signature of Gleason Score.
    Sinnott JA; Peisch SF; Tyekucheva S; Gerke T; Lis R; Rider JR; Fiorentino M; Stampfer MJ; Mucci LA; Loda M; Penney KL
    Clin Cancer Res; 2017 Jan; 23(1):81-87. PubMed ID: 27663590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of microRNA signature and potential pathway targets in prostate cancer.
    Moustafa AA; Ziada M; Elshaikh A; Datta A; Kim H; Moroz K; Srivastav S; Thomas R; Silberstein JL; Moparty K; Salem FE; El-Habit OH; Abdel-Mageed AB
    Exp Biol Med (Maywood); 2017 Mar; 242(5):536-546. PubMed ID: 27903835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes.
    Pascal LE; Vêncio RZ; Page LS; Liebeskind ES; Shadle CP; Troisch P; Marzolf B; True LD; Hood LE; Liu AY
    BMC Cancer; 2009 Dec; 9():452. PubMed ID: 20021671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.